132 related articles for article (PubMed ID: 38461938)
1. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
2. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
Trials; 2024 May; 25(1):312. PubMed ID: 38725072
[TBL] [Abstract][Full Text] [Related]
3. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
4. A systematic survey of randomised trials that stopped early for reasons of futility.
Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
[TBL] [Abstract][Full Text] [Related]
5. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
Walter SD; Han H; Briel M; Guyatt GH
Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
[TBL] [Abstract][Full Text] [Related]
6. A flexible futility monitoring method with time-varying conditional power boundary.
Ying Zhang ; Clarke WR
Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
[TBL] [Abstract][Full Text] [Related]
7. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
8. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
9. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
10. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
11. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
12. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
13. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
Bi D; Liu M; Lin J; Liu R
Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
Wang Y; Travis J; Gajewski B
BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
[TBL] [Abstract][Full Text] [Related]
15. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
16. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
Van Lancker K; Vandebosch A; Vansteelandt S
Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
[TBL] [Abstract][Full Text] [Related]
17. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
18. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
Wu X; Xu Y; Carlin BP
Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
[TBL] [Abstract][Full Text] [Related]
19. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
Barrado LG; Burzykowski T
Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
[TBL] [Abstract][Full Text] [Related]
20. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
